Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus
- 4 February 2018
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (5) , 1193-1201
Abstract
Aims: When treated with basal insulin peglispro (BIL), patients with type 1 diabetes mellitus (T1DM) exhibit weight loss and lower prandial insulin requirements versus insulin glargine (GL), while total insulin requirements remain similar. One possible explanation is enhanced lipid oxidation and improved ability to switch between glucose and lipid metabolism with BIL. This study compared the effects of BIL and GL on glucose and lipid metabolism in subjects with T1DM. Materials and Methods: Fifteen subjects with T1DM were enrolled into this open‐label, randomised, crossover study, and received once‐daily stable, individualised, subcutaneous doses of BIL and GL for 4 weeks each. Respiratory quotient (RQ) was measured using whole‐room calorimetry, and energy expenditure (EE) and concentrations of ketone bodies (3‐hydroxybutyrate) and acylcarnitines were assessed. Results: Mean sleep RQ was lower during the BIL (0.822) than the GL (0.846) treatment period, indicating greater lipid metabolism during the post‐absorptive period with BIL. Increases in carbohydrate oxidation following breakfast were greater during BIL than GL treatment (mean change in RQ following breakfast 0.111 for BIL, 0.063 for GL). Furthermore, BIL treatment increased total daily EE versus GL (2215.9 kcal/d for BIL, 2135.5 kcal/d for GL). Concentrations of ketone bodies and acylcarnitines appeared to be higher following BIL than GL treatment. Conclusions: BIL increased sleeping fat oxidation, EE, ketone bodies, acylcarnitines and post‐prandial glucose metabolism when switching from conventional insulin, thus, restoring metabolic flexibility and increasing thermogenesis. These changes may explain the previously observed weight loss with BIL versus GL.Keywords
Funding Information
- Eli Lilly and Company
This publication has 34 references indexed in Scilit:
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 DiabetesDiabetes Care, 2013
- Accuracy of Armband Monitors for Measuring Daily Energy Expenditure in Healthy AdultsMedicine & Science in Sports & Exercise, 2010
- Fasted to Fed Trafficking of Fatty Acids in Human Adipose Tissue Reveals a Novel Regulatory Step for Enhanced Fat StorageThe Journal of Clinical Endocrinology & Metabolism, 2009
- Alterations in hepatic glucose and energy metabolism as a result of calorie and carbohydrate restrictionHepatology, 2008
- Insulin therapy in renal diseaseDiabetes, Obesity and Metabolism, 2008
- Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusCochrane Database of Systematic Reviews, 2007
- Family History of Diabetes Links Impaired Substrate Switching and Reduced Mitochondrial Content in Skeletal MuscleDiabetes, 2007
- Insulin‐associated weight gain in diabetes – causes, effects and coping strategiesDiabetes, Obesity and Metabolism, 2006
- Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1994
- In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertensionDiabetes, 1993